Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03336658
Other study ID # 393/14
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 1, 2015
Est. completion date December 31, 2023

Study information

Verified date January 2023
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

All the preoperative biopsies of patients suffering colorectal cancer (CRC) will be immunohistochemically stained with a pancytokeratin marker to detect Tumor buds. then, the intratumoral buds (ITB) in the densest Region of Tumor buds, namely the "hot spot" will be counted. Subsequently, the probability of N stage (lymphnodes), M stage (metastases) and disease free survival (DFS) will be calculated based on an existing logistic Regression model already developed by our previous retrospective work. Additionally, a Standardisation of ITB using a well- established Software will develop an algorithm which will help to eliminate inter- observer variability of Tumor budding Counts.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 150
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with newly diagnosed stages I and IV colorectal cancer (CRC) - Age = 18 years - Written Informed Consent Exclusion Criteria: - No consent - < 18 years

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland Department of visceral surgery and transplant surgery, Berne University Hospital Berne

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary correlation of ITB based calculated N stage with real N stage in CRC - patients 24 months
Secondary correlation of ITB based calculated DFS with real DFS in CRC - patients 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Active, not recruiting NCT01308086 - Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer Phase 3
Active, not recruiting NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors Phase 1/Phase 2
Completed NCT03665285 - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06445062 - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Phase 1/Phase 2
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT05382377 - NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors Early Phase 1
Active, not recruiting NCT05314309 - Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening
Recruiting NCT06259552 - A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors Phase 1
Completed NCT05976282 - Addressing Colorectal Cancer in South Florida Firefighters N/A
Recruiting NCT01593098 - A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)
Recruiting NCT03597581 - A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer Phase 1
Terminated NCT05368688 - Microbiome in Colorectal Cancer Onset and Progression
Completed NCT03965845 - A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06455254 - Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM Phase 2
Not yet recruiting NCT03601598 - A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC Phase 1/Phase 2
Completed NCT02161549 - Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy N/A
Active, not recruiting NCT04868773 - Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy Phase 1